Unlocking the Fortress: Good News for Immunotherapy Directed to Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 3 trial: 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxA Phase 1 trial to keep an eye on: Thorium-227 (BAY2315497) in metastatic Castration Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxBenfo-Oxythiamine Shows Promise as a Radiosensitizer in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPositive Phase 1 Data Supports Phase 2 of 177Lu rhPSMA-10.1 for mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFDA Accepts New Drug Application for 3-Month Formulation of Leuprolide Mesylate for Advanced Prostate Cancer Treatment
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 2: Iodine-131 PSMA Radioligand with Enzalutamide Shows Promise in ARROW trial for metastatic castration-resistant prostate cancer (mCRPC)
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1 Trial of STX-478 Shows Promise for PI3K-Mutated Solid Tumors with Reduced Toxicity
/in Clinical Trial, Non-Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
- Newsletter 43/2025 October 26, 2025